Regeneron Pharmaceuticals Stock Analysis

REGN Stock  USD 823.72  15.13  1.87%   
The main objective of Regeneron Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Regeneron Pharmaceuticals is worth, separate from its market price. There are two main types of Regeneron Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Regeneron Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Regeneron Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Regeneron Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Regeneron Pharmaceuticals is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Regeneron Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Regeneron Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Regeneron Stock Analysis Notes

About 89.0% of the company shares are owned by institutional investors. The book value of Regeneron Pharmaceuticals was at this time reported as 234.47. The company has Price/Earnings To Growth (PEG) ratio of 1.74. Regeneron Pharmaceuticals recorded earning per share (EPS) of 35.09. The entity had not issued any dividends in recent years. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10915 people. To find out more about Regeneron Pharmaceuticals contact Leonard Schleifer at 914 847-7000 or learn more at

Regeneron Pharmaceuticals Quarterly Cost of Revenue

436.4 Million

Regeneron Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Regeneron Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Regeneron Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Over 89.0% of the company shares are owned by institutional investors
Latest headline from Regeneron Pharmaceuticals, Inc. Shares ... - MarketBeat

Regeneron Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Regeneron Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regeneron Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
2nd of February 2024
Upcoming Quarterly Report
2nd of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
2nd of February 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Regeneron Largest EPS Surprises

Earnings surprises can significantly impact Regeneron Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Regeneron Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Regeneron Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Regeneron Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Regeneron Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of November 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
5th of October 2023
Results of Operations and Financial Condition
27th of September 2023
Unclassified Corporate Event
25th of September 2023
Unclassified Corporate Event
12th of September 2023
Unclassified Corporate Event
8th of September 2023
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
25th of August 2023
Unclassified Corporate Event
18th of August 2023
Unclassified Corporate Event

Regeneron Pharmaceuticals Thematic Classifications

In addition to having Regeneron Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech Idea
Biotechnology and pharmaceuticals production and services
Cancer Fighters Idea
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Regeneron Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Last TransactionTypeSharesValue
Vanguard Group Inc2023-09-30Common Shares8.8 M7.2 B
State Street Corp2023-09-30Common Shares4.8 MB
Price T Rowe Associates Inc2023-09-30Common Shares2.2 M1.8 B
Wellington Management Group Llp2023-09-30Common Shares1.5 M1.2 B
Putnam Investments Llc2023-09-30Common Shares1.2 M976.4 M
Northern Trust Corp2023-09-30Common Shares1.1 M878.3 M
Morgan Stanley2023-09-30Common Shares971 K799.1 M
Norges Bank2022-12-31Common Shares966.5 K697.3 M
Neuberger Berman Group Llc2023-09-30Common Shares707.8 K582.6 M
Ubs Asset Management Americas Inc2023-09-30Common Shares695.4 K572.3 M
Sustainable Growth Advisers Lp2023-09-30Common Shares418.6 K344.5 M
Note, although Regeneron Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Regeneron Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 88.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regeneron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Regeneron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Regeneron Profitablity

Regeneron Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Regeneron Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Regeneron Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Regeneron Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Regeneron Pharmaceuticals' profitability requires more research than a typical breakdown of Regeneron Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.3 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.36 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.36.
Last ReportedProjected for 2023
Return on Investment 20.55  21.00 
Return on Average Assets 0.16  0.17 
Return on Average Equity 0.20  0.24 
Return on Invested Capital 0.21  0.28 
Return on Sales 0.40  0.43 

Management Efficiency

Regeneron Pharmaceuticals has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1722 %, meaning that it created $0.1722 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2023, Return on Investment is likely to grow to 21.00. Also, Return on Average Assets is likely to grow to 0.17. At this time, Regeneron Pharmaceuticals' Asset Turnover is very stable as compared to the past year. As of the 1st of December 2023, Return on Average Assets is likely to grow to 0.17, while Goodwill and Intangible Assets are likely to drop about 748.8 M.
Last ReportedProjected for 2023
Book Value per Share 211.62  228.32 
Enterprise Value over EBIT 16.00  19.44 
Enterprise Value over EBITDA 14.79  18.10 
Price to Book Value 3.47  5.44 
Tangible Assets Book Value per Share 264.23  285.09 
Enterprise Value77.8 B67.2 B
Tangible Asset Value28.3 B30.5 B
The analysis of Regeneron Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Regeneron Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Regeneron Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield
Forward Dividend Yield

Technical Drivers

As of the 1st of December, Regeneron Pharmaceuticals holds the Coefficient Of Variation of (2,773), risk adjusted performance of (0.025411), and Variance of 1.02. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regeneron Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Regeneron Pharmaceuticals, which can be compared to its competitors. Please check Regeneron Pharmaceuticals standard deviation and value at risk to decide if Regeneron Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 823.72 per share. Given that Regeneron Pharmaceuticals has information ratio of (0.046808), we recommend you to check out Regeneron Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Regeneron Pharmaceuticals Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Regeneron Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Regeneron Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Regeneron Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Regeneron Pharmaceuticals Outstanding Bonds

Regeneron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regeneron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regeneron bonds can be classified according to their maturity, which is the date when Regeneron Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Regeneron Pharmaceuticals Predictive Daily Indicators

Regeneron Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regeneron Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Regeneron Pharmaceuticals Forecast Models

Regeneron Pharmaceuticals' time-series forecasting models are one of many Regeneron Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Regeneron Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Regeneron Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Regeneron Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Regeneron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Regeneron Pharmaceuticals. By using and applying Regeneron Stock analysis, traders can create a robust methodology for identifying Regeneron entry and exit points for their positions.
Last ReportedProjected for 2023
Operating Margin 38.93  31.10 
EBITDA Margin 0.43  0.46 
Gross Margin 0.87  0.84 
Profit Margin 0.36  0.37 

Current Regeneron Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Regeneron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Regeneron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Regeneron Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Regeneron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Regeneron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Regeneron Pharmaceuticals, talking to its executives and customers, or listening to Regeneron conference calls.
Regeneron Analyst Advice Details

Regeneron Stock Analysis Indicators

Regeneron Pharmaceuticals stock analysis indicators help investors evaluate how Regeneron Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Regeneron Pharmaceuticals shares will generate the highest return on investment. By understating and applying Regeneron Pharmaceuticals stock analysis, traders can identify Regeneron Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow2.9 B
Long Term DebtB
Common Stock Shares Outstanding113.5 M
Total Stockholder Equity22.7 B
Total Cashflows From Investing Activities-3.8 B
Tax Provision520.4 M
Quarterly Earnings Growth Y O Y-0.238
Property Plant And Equipment Net3.8 B
Cash And Short Term Investments14.3 B
Cash3.1 B
Accounts Payable589.2 M
Net Debt-404.5 M
50 Day M A813.4488
Total Current Liabilities3.8 B
Other Operating Expenses7.2 B
Non Current Assets Total7.1 B
Forward Price Earnings18.797
Common Stock Total Equity100 K
Non Currrent Assets Other-4.7 B
Stock Based Compensation725 M
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Find actively traded Exchange Traded Funds (ETF) from around the world
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.